ISSN:
1573-0646
Keywords:
mitoxantrone
;
pancreatic carcinoma
;
phase II trial
;
DHAD
;
novantrone
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary Patient with advanced adenocarcinoma of the pancreas and no prior chemotherapy were treated on a Phase II trial of mitoxantrone. Doses were adjusted for hepatic dysfunction as defined by bilirubin. Twenty-four patients with a bilirubin ⩽ 1.5 mg% received mitoxantrone 12 mg/m2 i.v. repeated every three weeks. Myelosuppression in the form of leukopenia was the major toxicity. There were no responses in twenty-four evaluable patients.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00216928
Permalink